The four top-scoring MS abstracts submitted for AAN 2017 included 6-year outcomes with alemtuzumab treatment and pediatric MS environmental risk factors.
Chosen studies presented at AAN 2017 included an evaluation of cortical lesions in MS; 6-year outcomes of treatment with alemtuzumab in RRMS patients; an investigation of a possible link between viral infections, vitamin D deficiency, and pediatric-onset MS; and a look at the possibility of fatigue and lower limb problems predicting progression from RRMS to SPMS.Â
Longitudinal Characterization of Cortical Lesion Evolution in Multiple Sclerosis by Ultra High Field MRI
Compared to previous reports at lower field strength, the rate of cortical lesion accumulation was significantly increased, particularly in SPMS.
Durable Reduction in MRI Disease Activity with Alemtuzumab in the Absence ofContinuous Treatment in Patients with Active Relapsing-Remitting Multiple Sclerosis Who Were Treatment-Naive: 6-Year Follow-up of the CARE-MS I Study
What were the 6-year outcomes in active RRMS patients who were alemtuzumab treatment-naÃ¯ve at baseline?
Over 6 years, and in most cases in the absence of continuous treatment, alemtuzumab showed durable efficacy.
Environmental Risk Factors Associated with Pediatric MS: the Role of Remote Viral Infections and Vitamin D Revisited
Preliminary results suggest an association between prior EBV and HSV-1 infection, and vitamin D deficiency and pediatric-onset MS.
Self-Reported Fatigue and Lower Limb Problems Predictive of Conversion to Secondary Progressive Multiple Sclerosis in an Aging Sample of Patients